Valeant Pharmaceuticals Intl Inc (VRX) Given Average Recommendation of “Hold” by Analysts
Shares of Valeant Pharmaceuticals Intl Inc (TSE:VRX) (NYSE:VRX) have earned an average recommendation of “Hold” from the five brokerages that are presently covering the company, MarketBeat reports. Four analysts have rated the stock with a hold recommendation and one has given a buy recommendation to the company. The average 12-month price objective among brokers that have updated their coverage on the stock in the last year is C$23.33.
Several equities research analysts recently commented on VRX shares. TD Securities boosted their target price on Valeant Pharmaceuticals Intl to C$26.00 and gave the stock a “hold” rating in a report on Wednesday, July 12th. Cantor Fitzgerald reissued an “overweight” rating on shares of Valeant Pharmaceuticals Intl in a report on Thursday, June 29th. Finally, Royal Bank Of Canada reissued a “sector perform” rating and set a C$25.00 target price on shares of Valeant Pharmaceuticals Intl in a report on Monday, June 19th.
Shares of Valeant Pharmaceuticals Intl (TSE VRX) opened at 17.92 on Thursday. Valeant Pharmaceuticals Intl has a 12-month low of $11.20 and a 12-month high of $32.50. The company has a 50 day moving average price of $17.36 and a 200-day moving average price of $17.30. The firm’s market cap is $6.25 billion.
In other news, Director Schutter Richard Urbain De acquired 4,900 shares of the stock in a transaction on Monday, August 21st. The shares were purchased at an average cost of C$14.35 per share, for a total transaction of C$70,315.00. Also, Director John Paulson sold 24,700 shares of Valeant Pharmaceuticals Intl stock in a transaction that occurred on Wednesday, August 9th. The stock was sold at an average price of C$14.66, for a total transaction of C$362,102.00.
About Valeant Pharmaceuticals Intl
Valeant Pharmaceuticals International, Inc is a pharmaceutical and medical device company. The Company is engaged in developing and marketing a range of branded, generic and branded generic pharmaceuticals, over-the-counter (OTC) products, and medical devices (contact lenses, intraocular lenses, ophthalmic surgical equipment, and aesthetics devices).
Receive News & Ratings for Valeant Pharmaceuticals Intl Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valeant Pharmaceuticals Intl Inc and related companies with MarketBeat.com's FREE daily email newsletter.